Drug intelligence / Profile preview

E8001

Development stage: Phase 1
Lead developer: Eisai
Modality: Small Molecules
Administration: Intravenous

Overview

E8001 is an investigational small molecule drug developed by Eisai for the prevention or treatment of rejection reactions associated with organ transplantation. The drug is administered intravenously and has undergone Phase 1 clinical trials in healthy volunteers in Japan. As of February 2025, its mechanism of action remains undefined and it has not received regulatory approval for any indication. No orphan drug status or FDA designation has been granted to date[1][2][3].

Other names: E-8001E8001E 8001

Beyond the preview

Go deeper on E8001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on E8001.

Explore the full profile